Cardiovascular Drugs and Therapy

, Volume 23, Issue 4, pp 295–299 | Cite as

Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?

  • Bunyamin YavuzEmail author
  • Derun Taner Ertugrul
  • Hicran Cil
  • Naim Ata
  • Kadir Okhan Akin
  • Ahmet Arif Yalcin
  • Metin Kucukazman
  • Kursad Dal
  • Murat Sevket Hokkaomeroglu
  • Burcu Balam Yavuz
  • Emre Tutal



Low levels of 25-hydroxyvitamin D are associated with higher risk of cardiovascular morbidity and mortality. Large trials demonstrated that statins significantly decrease cardiovascular morbidity and mortality. 7-dehydrocholesterol is the precursor of both cholesterol and vitamin D. The aim of this study was to investigate the possible effect of rosuvastatin on vitamin D metabolism.


The study was performed in a prospective cohort design. The study group consisted of 91 hyperlipidemic patients who had not been treated with lipid lowering medications. Lipid parameters, 25 hydroxyvitamin-D, 1,25-dihydroxyvitamin D, and bone alkaline phosphatase were obtained at baseline and after 8 weeks of rosuvastatin treatment.


None of the subjects withdrew from the study because of the adverse effects. The mean age was 59.9 ± 12.5 years. The majority of the patients were male (55, 60%). Seventeen patients were diabetic, and 43 patients had systemic hypertension. There was a significant increase in 25-hydroxyvitamin D, from mean 14.0 (range 3.7– 67) to mean 36.3 (range 3.8 –117) ng/ml (p < 0.001), and also an increase of 1,25-dihydroxyvitamin D from mean 22.9 ± 11.2 to 26.6 ± 9.3 pg/dl (p = 0.023). Bone alkaline phosphatase decreased after 8 weeks of rosuvastatin treatment, mean 17.7 (range 2.6–214) to mean 9.5 (range 2.3–19.1) u/l (p < 0.001) rosuvastatin treatment.


This study has shown an effect of rosuvastatin on vitamin D metabolism, with an increase in both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. This may be an important pleiotropic effect whereby rosuvastatin reduces mortality in patients with coronary artery disease. Further studies are needed to clarify the relationship between statins and vitamin D metabolism.

Key words

25 hydroxyvitamin-D 1,25-dihydroxyvitamin D Rosuvastatin Pleiotropic effect Statin 


  1. 1.
    Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–80.2.PubMedCrossRefGoogle Scholar
  2. 2.
    Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary heart disease. Q J Med. 1996;89:579–89.Google Scholar
  3. 3.
    Mortimer EA, Monson RR, MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N EngI J Med. 1977;296:581–85.CrossRefGoogle Scholar
  4. 4.
    Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;3342:757–61.CrossRefGoogle Scholar
  5. 5.
    Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205–1209.PubMedGoogle Scholar
  6. 6.
    Shepherd J, Cobbe SM, Ford I, for the West of Scotland Coronary Prevention Study Group, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EngI J Med. 1995;333:1301–7.CrossRefGoogle Scholar
  7. 7.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383–9.Google Scholar
  8. 8.
    Guryev O, Carvalho RA, Usanov S, Gilep A, Estabrook RW. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc NatI Acad Sci USA. 2003;100:14754–14759.CrossRefGoogle Scholar
  9. 9.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486–97.CrossRefGoogle Scholar
  10. 10.
    Wilczek H, Sobra J, Justova V, Ceska R, Juzova Z, Prochazkova R, et al. latropathogenic effect of mevacor on vitamin D metabolism. Cas Lek Cesk. 1989;128:1254–1256.PubMedGoogle Scholar
  11. 11.
    Wilzcek H, Sobra J, Ceska R, Justota V, Juzova Z, Prochazkova R, et al. Monitoring plasma levels of vitamin D metabolites in simvastatin therapy in patients with familial hypercholesterolemia. Cas Lek Cesk. 1994;133:727–729.Google Scholar
  12. 12.
    Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99:903–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering — are they clinically relevant? Eur Heart J. 2003;24:225–48.PubMedCrossRefGoogle Scholar
  14. 14.
    Grimes DS. Are statins analogues of vitamin D? Lancet. 2006;368:83–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–37.PubMedCrossRefGoogle Scholar
  16. 16.
    Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int. 2005;16:990–998.PubMedCrossRefGoogle Scholar
  17. 17.
    Safaei H, Janghorbani M, Aminorroaya A, Amini M. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007;44:76–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Uysal AR, Delibasi T, Erdogan MF, et al. Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract. 2007;13:114–6.PubMedGoogle Scholar
  19. 19.
    Svejda P, Soska V, Soucek M. The impact of statin therapy on bone density changes in postmenopausal women. Vnitr Lek. 2007;53:1064–70.PubMedGoogle Scholar
  20. 20.
    Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM. Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int. 2005;16:1272–1276.PubMedCrossRefGoogle Scholar
  21. 21.
    Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur J Clin Invest. 2002;32:581–589.PubMedCrossRefGoogle Scholar
  22. 22.
    Kajinami K, Takekoshi N, Matsui S, Kanemitsu S, Okubo S, Kanayama S, et al. Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1113–1116.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Bunyamin Yavuz
    • 1
    • 5
    Email author
  • Derun Taner Ertugrul
    • 2
  • Hicran Cil
    • 2
  • Naim Ata
    • 2
  • Kadir Okhan Akin
    • 3
  • Ahmet Arif Yalcin
    • 1
  • Metin Kucukazman
    • 2
  • Kursad Dal
    • 2
  • Murat Sevket Hokkaomeroglu
    • 2
  • Burcu Balam Yavuz
    • 4
  • Emre Tutal
    • 2
  1. 1.Kecioren Teaching and Research HospitalDepartment of CardiologyAnkaraTurkey
  2. 2.Kecioren Teaching and Research HospitalDepartment of Internal MedicineAnkaraTurkey
  3. 3.Kecioren Teaching and Research HospitalDepartment of BiochemistryAnkaraTurkey
  4. 4.Hacettepe University Faculty of MedicineDepartment of Internal MedicineAnkaraTurkey
  5. 5.Kecioren Teaching and Research HospitalDepartment of CardiologyKeciorenTurkey

Personalised recommendations